

Sydney Today  16° / 24° >**The Daily Telegraph**
We're for youHi, George My
News
Today's
Paper

NSW

World

Sport

Business

Opinion

Education

Health

Lifestyle


Entertainment

Puzzles




Business Stockhead

The dementia challenge: Which ASX



The search for a dementia breakthrough is gathering pace in Australia and around the world. Pic: Getty Images

Dementia is one leading cause of death in Australia while ranking among major causes of disability and dependency in older people



dependency among older people.

Stockhead

Everything you need to know before the ASX opens in Australia, [dementia is the leading cause of death](#), while globally it ranks among the major causes of disability and dependency in older people. [Dementia is the leading cause of death](#), while globally it ranks among the major causes of disability and dependency in older people. [Dementia is the leading cause of death](#), while globally it ranks among the major causes of disability and dependency in older people.

That research effort includes Australia, which is marking Dementia Action Week. To coincide with the week, seven Australian startups were announced as recipients of a combined \$15.6 million in funding to accelerate the development of new treatments, diagnostics and technologies for dementia and cognitive decline.

The funding is the second round for the Australian Government's Medical Research Future Fund (MRFF) CUREator+ Dementia & Cognitive Decline national program, run by Brandon BioCatalyst in partnership with ANDHealth and Dementia Australia.



Alzheimer's trials to potential treatments and therapies targeting the shared biology underlying multiple neurodegenerative diseases.

Felix Gold chases US antimony dream

Morgan's senior healthcare analyst Scott Power told Stockhead, dementia was a major area of unmet need, with significant investment around the world focused on tackling the disease.

"If you get close to cracking the nut or providing some sort of treatment options for patients that is going to be extremely valuable," he said. [Read More >](#)



Leaders & Companies

Cogstate (ASX:CGS) is working with several big pharma companies as they work to develop potential treatments for Alzheimer's disease, which is the most common cause of dementia, including US-based Eli Lilly and Japanese drug developer, Eisai.

□

SA News

Mayfair Hotel to be transformed after \$75m sale

□

Business

Digital air traffic control towers not fit for WFH, says

Airservices boss

□

CEO Brad O'Connor told Stockhead CGS managed the cognitive endpoints and data quality for Lilly's successful pivotal phase III trial of donanemab (brand name Kisunla).

The drug received FDA approval in 2024 as a disease-modifying treatment for people with early Alzheimer's disease.



EXCLUSIVE Central Coast

Woman sentenced over foiled tobacco tsar robbery

by the FDA in 2023.


□



NRL

One man – and one song – to end NRL's GE entertainment debate

□



UPDATED Breaking News

'In tears': Secret side of Aussie rock legend

□

CGS manages cognitive endpoints on behalf of pharmaceutical companies, using a combination of technology and human services to ensure the quality of data collected at clinical trial sites for Alzheimer's and other neurodegenerative diseases.

NRL

Perth Bears poised to play for Mitchell

"We're managing, on behalf of the pharmaceutical companies, all of the cognitive endpoints, to ensure the accuracy and quality of the data that's

cognitive

Celebrity Life

Only person Dolly Parton wanted by deathbed

Let Them Be Kids



being collected."

Major Aus car dealership cops maximum fine

He said that work includes.



'Ultimate sycophant': Harry hails Aussie social media ban, warns of AI threat



NSW

- Training staff at clinical trial sites (research hospitals)
- Monitoring (auditing) data to ensure quality
- Delivery of telehealth assessments by Cogstate's 400-consulting neuropsychologists in \$8m
- Algorithmic and human monitoring of data



What? Australian council's 39k fines rakes



National

'Unacceptable': PM

O'Connor said all these security sites are compromised



Puzzles

chnology were designed to identify Boy George gained fame in the 1980s as the lead singer of what band?



CGS is now managing cognitive endpoints and ensuring data quality for both Lilly and Eisai as they investigate whether their approved early Alzheimer's treatments can be used even

What about me?

Shannon Noll puts hand up for NRL grand final

O'Connor said the companies were moving into treating "pre-sym" "pre-clinical" Alzheimer's disease, where people may have amyloid in their brains but do not yet have the memory impairment associated with dementia.



Celebrity

Shock lives of 40yo Hanson brothers now



"It's sort of akin to treating cholesterol to prevent heart disease," O'Connor said, referring to the prospect of treating amyloid accumulation before significant cognitive symptoms develop.

"These plaques can occur up to 20 years before symptoms arrive.

"The hypothesis is that if removed through treatment before symptoms, can the symptoms be stopped from ever occurring."

He said the shift toward treating Alzheimer's earlier was also being enabled by advances in blood-based biomarkers.

In July 2026, Australia's Therapeutic Goods Administration (TGA) approved a blood test that can help identify amyloid pathology associated with Alzheimer's disease.

Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) test was developed in collaboration with Eli Lilly and was also cleared in August by the FDA.

"Eli Lily's and Eisai 's phase III trials are expected to conclude in 2027 and if they work Alzheimer's has changed forever because we now start treating people at the pre-symptomatic stage," O'Connor said.

CGS also has a Cognigram Digital Cognitive Assessment System, used by physicians to measure cognitive function and detect changes over time.

It assesses areas including processing speed, attention, visual learning, working memory, visual motor function and executive function.

The test can be used to assess cognition at a single point in time or track cognitive change through periodic assessments.

"There is a potential future where a simple blood test can identify the formation of plaques in the brain," O'Connor said.

"Cogstate digital assessments can then identify any functional impairment which will provide insight into the potential rate of decline.

"Then, through drugs approved for use in this earlier stage of disease, we can remove plaques before the horrendous memory impairment takes hold. It is super exciting."

Countdown to Actinogen's phase III Alzheimer's trial readout

[Actinogen Medical \(ASX:ACW\)](#) is the only ASX-listed healthcare company with an advanced program focused on Alzheimer's disease.

ACW's lead candidate Xanamem is in a phase 2b/3 trial dubbed XanaMIA, with topline results expected in November.

Xanamem is described by the company as the "first and only potent oral inhibitor of 11 β -HSD1", an enzyme involved in regulating cortisol in brain regions linked to memory and mood.

The oral drug candidate is designed to reduce excess cortisol production in the brain while preserving normal cortisol levels elsewhere in the body, with the aim of slowing cognitive decline.

"As national conversations around brain health take centre stage for Dementia Action Week, our team is staying sharply focused on our November trial readout," ACW chief financial officer Will Souter told Stockhead.

"We are rapidly approaching a pivotal moment that we hope will deliver a meaningful new treatment option for patients and their families."

"Dementia Action Week is a timely reminder of why we do what we do every day at Actinogen.

With trial sites fully enrolled and our upcoming November results on track, we are working hard to advance Xanamem toward becoming a potential breakthrough in Alzheimer's care."

Alterity eyes broader dementia potential for lead drug

[Alterity Therapeutics \(ASX:ATH\)](#) is developing its lead asset ATH434 for multiple system atrophy (MSA), a rare and aggressive Parkinsonian disorder.

The neurodegenerative disease, which affects up to 50,000 patients in the US, is characterised by the build-up of excess iron and aggregation of a protein called alpha-synuclein in the central nervous system (CNS).

ATH said the underlying biology is relevant across a broader group of neurodegenerative diseases.

Alpha-synuclein is a shared hallmark of MSA, Parkinson's disease, and dementia with Lewy bodies, one of the most common forms of dementia after Alzheimer's disease. Alzheimer's itself is driven by different proteins, amyloid-beta and tau.

The company describes ATH434 as an "iron chaperone", an orally administered small molecule designed to redistribute excess reactive iron within brain cells.

"ATH434 targets excess reactive iron in the brain, a key driver of alpha-synuclein misfolding," CEO Dr David Stamler told Stockhead.

"Right now our focus is on Multiple System Atrophy, a rapidly progressing disease with no approved therapy.

"The alpha-synuclein protein misfolds in a number of other neurodegenerative diseases, including dementia with Lewy bodies and in Parkinson's disease, where many patients develop dementia."

In preclinical models of MSA and Parkinson's disease, ATH434 reduced alpha-synuclein aggregation, preserved neurons, and improved motor function.

ATH is preparing for a phase III trial of ATH434 in MSA after reaching agreement with the US Food and Drug Administration (FDA) at an End-of-Phase 2 meeting on key elements of the study design, including the dose and primary endpoint. ATH434 has FDA Fast Track designation and orphan drug designation in the US and EU.

While MSA is ATH's immediate focus, the company sees potential for ATH434 to be explored in other neurodegenerative diseases, including dementia with Lewy Bodies.

"The biology we are targeting is shared across these conditions, which is why the mechanism is relevant well beyond MSA," Stamler said.

The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

At Stockhead, we tell it like it is. While Alterity Therapeutics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [The dementia challenge: Which ASX stocks are chasing a breakthrough?](#)

Business Newsletter

Hi George,

[Sign up](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription Packages	About us	Help & support	Herald Sun	Buy Search Sell Classifieds	 
Group/Corporate subscriptions	Meet the team	FAQs	Courier Mail	Find Your Local	
The Daily Telegraph app	Job opportunities	Standards of practice	The Advertiser	Foxsports	
Today's Paper	Code of conduct	Letter to the Editor	news.com.au	Foxtel	
Newsletters	Subscriptions FAQs	Licensing & Reprints	The Australian	Hipages	
	Subscription terms	Advertise with us	The Mercury	Kayo	
	Financial Hardship Policy		Geelong Advertiser	My Tributes	
			Punters		
			The Cairns Post	odds.com.au	
			Gold Coast Bulletin	racenet.com.au	
			Townsville Bulletin	realestate.com.au	
			News24 Australia		
			The Chronicle	Coupons	
			NT News		
			The Weekly Times		
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network.Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#) [Relevant ads opt-out](#) [Cookie policy](#) [Terms of use](#)